All In Biotech

Drug Trial Radar · NCT01646437

The International Polycap Study 3 (TIPS-3)

The International Polycap Study 3 (TIPS-3) is a Randomized Double-blind Placebo-controlled Trial for the Evaluation of a Polycap, Low Dose Aspirin and Vitamin D Supplementation in Primary Prevention

Last checked: Nov 20, 2026Latest source record: Sep 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 7,793 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

7,793

Actual

Start

Jun 2012

Primary completion

Jun 30, 2020

Study completion Aug 30, 2021

Sponsor

Lead sponsor
Population Health Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cadila Pharnmaceuticals; Wellcome Trust; Canadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of Ontario
First posted
Jul 20, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The randomized 2x2x2 factorial design placebo controlled trial will enroll 5000 participants (women 60 years or older and men 55 years or older) without known heart disease or prior stroke and without a clear indication or contraindication to any of the study medications. Eligible and consenting individuals will be randomized to receive either the active study medications or placebo (dummy pills) and will be monitored for an average of 5 years. The study will include people from at 10 countries, will be conducted by an international group of scientists and physicians and will be coordinated by the Population Health Research Institute at Hamilton Health Sciences.

Conditions

  • Cardiovascular Disease
  • Fractures
  • Cancers

Interventions

  • PolycapDrug

    Polycap (thiazide 25mg, atenolol 100mg, ramipril 10mg, simvastatin 40mg) taken once daily

  • AspirinDrug

    75 mg daily

  • Vitamin DDrug

    60,000 IU monthly

  • Matching PlaceboDrug

    Matching Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Polycap Primary ObjectiveTime frame: Participants will be followed for an average of 4.25 years
  2. Aspirin Primary ObjectiveTime frame: Participants will be followed for an average of 4.25 years
  3. Vitamin D Primary ObjectiveTime frame: Participants will be followed for an average of 4.25 years
  4. Combined Effects of Polycap and Aspirin on CVD EventsTime frame: Participants will be followed for an average of 4.25 years

Locations

9 sites in 9 countries. Site status is shown where the registry gives one.

  • Eminence

    Dhaka, Bangladesh

  • Hamilton Health Sciences

    Hamilton, Ontario, Canada

  • Fundaction Oftamologica De Santander (FOSCAL)

    Bucaramanga, Colombia

  • St. John's Medical College Hospital

    Bangalore, India

  • Harapan Kita Hopsital

    Jakarta, Indonesia

  • Universiti Teknologi MARA (UiTM)

    Shah Alam, Selangor, Malaysia

  • Adult Medicine & Medical Research Unit, Philippine General Hospital

    Manila, Philippines

  • Pamoja Tunaweza Women's Centre

    Moshi, Tanzania

  • Fattouma Bourguiba University Hospital

    Monastir, Tunisia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.